Related references
Note: Only part of the references are listed.Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells
Al Hassan Kyakulaga et al.
Oncotarget (2020)
Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer
Nafees Muhammad et al.
INORGANIC CHEMISTRY (2020)
Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
David P. Hill et al.
BMC CANCER (2019)
Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
Jessa Gilda P. Pandy et al.
BMC CANCER (2019)
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Xiang Ling et al.
ACS NANO (2019)
Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy
Tomaz Makovec
RADIOLOGY AND ONCOLOGY (2019)
Cisplatin nephrotoxicity: a review of the literature
Sandhya Manohar et al.
JOURNAL OF NEPHROLOGY (2018)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Ferroptosis: A Novel Anti-tumor Action for Cisplatin
Jipeng Guo et al.
CANCER RESEARCH AND TREATMENT (2018)
Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance
Feihong Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises
Nikolaos Garmpis et al.
CANCER GENOMICS & PROTEOMICS (2017)
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
Timothy C. Johnstone et al.
CHEMICAL REVIEWS (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells
Vojtech Novohradsky et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Therapeutic targets of triple-negative breast cancer: a review
Vinayak S. Jamdade et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Reprogramming the Mechanism of Action of Chlorambucil by Coupling to a G-Quadruplex Ligand
Marco Di Antonio et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Systems biology of cisplatin resistance: past, present and future
L. Galluzzi et al.
CELL DEATH & DISEASE (2014)
Cisplatin: an old drug with a newfound efficacy - from mechanisms of action to cytotoxicity
Antonio Maccio et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
Rossella Marullo et al.
PLOS ONE (2013)
Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells
Ganna V. Kalayda et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Conjugate of Pt(IV)-Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy
Jun Yang et al.
MOLECULAR PHARMACEUTICS (2012)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Positive feedback of G1 cyclins ensures coherent cell cycle entry
Jan M. Skotheim et al.
NATURE (2008)
Reaction of dicarbonates with carboxylic acids catalyzed by weak Lewis acids: General method for the synthesis of anhydrides and esters
Giuseppe Bartoli et al.
SYNTHESIS-STUTTGART (2007)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)
A Ghezzi et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells
MD Hall et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2003)
Regulation of cell death: The calcium-apoptosis link
S Orrenius et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Cisplatin biochemical mechanism of action:: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways
MA Fuertes et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Selective cancer cell killing by α-tocopheryl succinate
J Neuzil et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
